Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report

References

• BellmuntJOrsolaALeowJJBladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-upAnn Oncol201425Suppl 3iii40iii4825096609
   PubMed Web of Science ®Google Scholar
• BalarAVGalskyMDRosenbergJEAtezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialLancet201738910064677627939400
   PubMed Web of Science ®Google Scholar
• StewartRMorrowMHammondSAIdentification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibodyCancer Immunol Res2015391052106225943534
   PubMed Web of Science ®Google Scholar
• RosenbergJEHoffman-CensitsJPowlesTAtezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialLancet2016387100311909192026952546
   PubMed Web of Science ®Google Scholar
• PowlesTEderJPFineGDMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature2014515752855856225428503
   PubMed Web of Science ®Google Scholar
• PowlesTO’DonnellPHMassardCEfficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label studyJAMA Oncol201739e17241128817753
   PubMed Web of Science ®Google Scholar
• MassardCGordonMSSharmaSSafety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancerJ Clin Oncol201634263119312527269937
   PubMed Web of Science ®Google Scholar
• SyedYYDurvalumab: first global approvalDrugs201777121369137628643244
   PubMed Web of Science ®Google Scholar
• Saâda-BouzidEDefaucheuxCKarabajakianAHyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinomaAnn Oncol20172871605161128419181
   PubMed Web of Science ®Google Scholar
• ChubachiSYasudaHIrieHA case of non-small cell lung cancer with possible “disease flare” on nivolumab treatmentCase Rep Oncol Med2016201613
   Google Scholar
• YoshidaTFurutaHHidaTRisk of tumor flare after nivolumab treatment in patients with irradiated field recurrenceMed Oncol20173433434
   Web of Science ®Google Scholar
• AlexanderGSPalmerJDTulucMImmune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapyJ Hematol Oncol2016919627663515
   PubMed Web of Science ®Google Scholar
• ChampiatSDercleLAmmariSHyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1Clin Cancer Res20172381920192827827313
   PubMed Web of Science ®Google Scholar
• KatoSGoodmanAWalavalkarVBarkauskasDASharabiAKurzrockRHyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rateClin Cancer Res201723154242425028351930
   PubMed Web of Science ®Google Scholar
• ZouWChenLInhibitory B7-family molecules in the tumour micro-environmentNat Rev Immunol20088646747718500231
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• FerrisRLBlumenscheinGFayetteJNivolumab for recurrent squamous-cell carcinoma of the head and neckN Engl J Med2016375191856186727718784
   PubMed Web of Science ®Google Scholar
• RobertsonAGKimJAl-AhmadieHComprehensive molecular characterization of muscle-invasive bladder cancerCell20181744103330096301
   PubMed Web of Science ®Google Scholar
• KriegmairMCBalkMWirtzRExpression of the p53 inhibitors MDM2 and MDM4 as outcome predictor in muscle-invasive bladder cancerAnticancer Res201636105205521427798881
   PubMed Web of Science ®Google Scholar
• KleffelSPoschCBarthelSRMelanoma cell-intrinsic PD-1 receptor functions promote tumor growthCell201516261242125626359984
   PubMed Web of Science ®Google Scholar
• WadeMLiYCWahlGMMDM2, MDMX and p53 in oncogenesis and cancer therapyNat Rev Cancer2013132839623303139
   PubMed Web of Science ®Google Scholar
• WatanabeMMoonKDVacchioMSHathcockKSHodesRJDownmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responsesImmunity201440568169124792911
   PubMed Web of Science ®Google Scholar
• PengWLiuCXuCPD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokinesCancer Res201272205209521822915761
   PubMed Web of Science ®Google Scholar
• SchindlerCLevyDEDeckerTJAK-STAT signaling: from interferons to cytokinesJ Biol Chem200728228200592006317502367
   PubMed Web of Science ®Google Scholar
• WaightJDNetherbyCHensenMLMyeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axisJ Clin Invest2013123104464447824091328
   PubMed Web of Science ®Google Scholar
• ZhaoYYuHHuWThe regulation of MDM2 oncogene and its impact on human cancersActa Biochim Biophys Sin (Shanghai)201446318018924389645
   PubMed Web of Science ®Google Scholar
• GordonSRMauteRLDulkenBWPD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunityNature2017545765549549928514441
   PubMed Web of Science ®Google Scholar
• LuXHornerJWPaulEEffective combinatorial immunotherapy for castration-resistant prostate cancerNature2017543764772873228321130
   PubMed Web of Science ®Google Scholar
• NewcombEWDemariaSLukyanovYThe combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomasClin Cancer Res200612154730473716899624
   PubMed Web of Science ®Google Scholar
• DovediSJAdlardALLipowska-BhallaGAcquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockadeCancer Res201474195458546825274032
   PubMed Web of Science ®Google Scholar
• WalshawRCHoneychurchJIllidgeTMChoudhuryAThe anti-PD-1 era – an opportunity to enhance radiotherapy for patients with bladder cancerNat Rev Urol201815425125929089607
   PubMed Web of Science ®Google Scholar
• GalluzziLBuquéAKeppOZitvogelLKroemerGImmunological effects of conventional chemotherapy and targeted anticancer agentsCancer Cell201528669071426678337
   PubMed Web of Science ®Google Scholar
• DossetMVargasTRLagrangeAPD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancerOncoimmunology201876e143398129872568
   PubMed Web of Science ®Google Scholar
• SongWShenLWangYSynergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trapNat Commun201891223729884866
   PubMed Web of Science ®Google Scholar